BridgeBio Pharma发行5.5亿美元2033年到期可转换优先票据 用于提前偿还2027年到期票据

美股速递
Jan 16

BridgeBio Pharma, Inc.宣布完成5.5亿美元2033年到期可转换优先票据的定价发行。此次发债所得资金将主要用于提前偿还公司2027年到期的可转换优先票据,通过债务期限管理优化公司财务结构。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10